Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Awakn Life Sciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.07.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Awakn Life Sciences. This rating has held steady since March 2023, when it changed from a Buy consensus rating.
Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.
Read More